Diabetes mellitus classification;Classificação do diabete melito

Arquivos Brasileiros de Cardiologia

Volumn 95, Issue 2, 2010, Pages

  Maraschin, Jorge De Faria ^a   Murussi, Nádia ^a   Witter, Vanessa ^a   Silveiro, Sandra Pinho ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

C peptide; Carboxylyases; Diabetes mellitus classification; Glutamic acid

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; PANCREAS ISLET CELL ANTIBODY; PROINSULIN;

ANTIBODY DETECTION; AUTOIMMUNITY; CLASSIFICATION ALGORITHM; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY DIABETES MELLITUS; PROTEIN FUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY;

AUTOANTIBODIES; AUTOIMMUNITY; C-PEPTIDE; DIABETES MELLITUS; GLUTAMATE DECARBOXYLASE; HUMANS;

EID: 77957314644     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21: 292-6.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-53.
3. Gross JL, Silveiro SP, Camargo JL, Reichelt AJ, Azevedo MJ. Diabetes melito: diagnóstico, classificação e avaliação do controle glicêmico. Arq Bras Endocrinol Metab. 2002; 46: 16-26.
4. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28: 164-76.
5. Campagnolo N, Murussi N, Silveiro SP. Diabete melito. In: von Exe Colerta, Capp E. (orgs.). Ginecologia no consultório. São Paulo: Artmed; 2008. p. 519-41.
6. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Position Statement. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific statement of the American College of Cardiology; Foundation and the American Heart Association. Diabetes Care. 2009; 32: 187-92.
7. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20: 1183-97.
8. World Health Organization Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia : Report of a WHO/IDF consultation. Geneva: WHO; 2006.
9. American Diabetes Association. Position Statement. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009; 32: S62-S67.
10. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008; 29: 292-302.
11. Reinehr T, Schober E, Wiegand S, Thon A, Holl R, DPV-Wiss Study Group. Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child. 2006; 91: 473-7.
12. Campagnolo N, Dallapicola PF, Murussi N, Canani LH, Gross JL, Silveiro SP. Aspectos clínicos e moleculares do Maturity Onset Diabetes of the Young (MODY). Revista do Hospital de Clínicas de Porto Alegre. 2005; 24: 51-9.
13. Buse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders Elsevier; 2008. p. 1329-89.
14. Eisenbarth GS, Polonsky KS, Buse JB. Type 1 diabetes mellitus. In: Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders Elsevier; 2008. p. 1391-416.
15. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990; 347: 151-6.
16. Lan MS, Wasserfall C, Maclaren NK, Notkins AL IA-2. A transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA. 1996; 93: 6367-70. (Pubitemid 26230311)
17. Mire-Sluis AR, Das RG, Lernmark Å. The World Health Organization International collaborative study for islet cell antibodies. Diabetologia. 2000; 43: 1282-92.
18. Bingley PJ, Bonifacio E, Mueller PW: Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes. 2003; 52: 1128-36.
19. Bottazzo GF, Gleichmann H. Immunology and diabetes workshops: report of the first international workshop on the standardisation of cytoplasmic islet cell antibodies. Diabetologia. 1986; 29: 125-6.
20. Winter WE, Harris N, Schatz D. Immunological markers in the diagnosis and prediction of autoimmune Type 1a diabetes. Clin Diabetes. 2002; 20: 183-91.
21. Marner B, Agner T, Binder C, Lernmark Å, Nerup J, Mandrup-Poulsen T. Increased reduction in fasting C-peptide is associated with islet cell antibodies in Type 1 (insulin-dependent) diabetic patients. Diabetologia. 1985; 28: 875-80.
22. Landin-Olsson M, Karlsson FA, Lernmark A, Sundkvist G. Islet cell and thyrogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the Diabetes Incidence Study in Sweden. Diabetes. 1992; 41: 1022-7.
23. Schiffrin A, Ciampi A, Hendricks L, Rozen R, Weitzner G. Evidence for different clinical subtypes of type 1 diabetes mellitus: a prospective study. Diabet Res Clin Pract. 1994; 23: 95-102.
24. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. for UK Prospective Diabetes Study (UKPDS) Group UKPDS 25. Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet. 1997; 350: 1288-93.
25. Ziegler AG. The Fourth International Workshop on the Standardisation of Insulin Autoantibody Measurement. Diabetologia. 1990; 33: 683-9.
26. Eisenbarth GS, Jackson RA, Pugliese A. Insulin autoimmunity: the rate limiting factor in pre-type I diabetes. J Autoimmun. 1992; 5: 241-6.
27. Knip M: Natural course of preclinical type 1 diabetes. Horm Res. 2002; 57: 6-11. (Pubitemid 34458074)
28. Karlsen AE, Hagopian WA, Grubin CE, Dube S, Disteche CM, Adler DA, et al. Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci. 1991; 88: 8337-41.
29. Bu DF. Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci. 1992; 89: 2115-9.
30. Vandewalle CL, Falorni A, Svanholm S, Lernmark A, Pipeleers DG, Gorus FK. High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J Clin Endocrinol Metab. 1995; 80: 846-51.
31. Verge CF, Howard NJ, Rowley MJ, Mackay IR, Zimmet PZ, Egan M, et al. Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study. Diabetologia. 1994; 37: 1113-20.
32. Aanstoot HJ, Sigurdsson E, Jaffe M, Shi Y, Christgau S, Grobbee D, et al. Value of antibodies to GAD65 combined with islet cell cytoplasmic antibodies for predicting IDDM in a childhood population. Diabetologia. 1994; 37: 917-24.
33. Maraschin JF. Acurácia diagnóstica do anticorpo anti-descarboxilase do ácido glutâmico (anti-GAD) como marcador de auto-imunidade no diabete melito. [Dissertação]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2007.
34. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes. 1999; 48: 460-8. (Pubitemid 29106857)
35. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab. 2003; 88: 103-8.
36. Verge CF. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996; 45: 926-33.
37. Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Bottazzo GF, Gale EAM. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes. 1997; 46: 1701-10.
38. Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004; 53: 384-92.
39. Leslie RD, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Diabetologia. 1999; 42: 3-14.
40. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest. 1986; 77: 98-105. (Pubitemid 16101207)
41. The DCCT Research Group: Effect of intensive therapy on residual β-cell function in patients with type I diabetes in the Diabetes Control and Complications Trial. Ann Intern Med. 1998; 128: 517-23.
42. Nakanishi K, Kobayashi T, Miyashita H, Ohkubo M, Sugimoto T, Murase T, et al. Relationships among islet cell antibodies, residual β-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay. Metabolism. 1990; 39: 925-30.
43. Sjoberg S, Gunnarsson R, Gjotterberg M, Lefvert AK, Persson A, Osterman J. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulindependent) diabetes mellitus. Diabetologia. 1987; 30: 208-13.
44. Sjoberg S, Gjotterberg M, Berglund L, Moller E, Osterman J. Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type 1 (insulin-dependent) diabetes mellitus. J Diabet Complications. 1991; 1: 18-22.
45. The DCCT Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab. 1987; 65: 30-6.
46. Palmer JP, Fleming AG, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, et al. C-Peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: ADA Workshop Report. Diabetes. 2004; 53: 250-64.
47. Faber OK, Kehlet H, Madsbad S, Binder C. Kinetics of human C-peptide in man. Diabetes. 1978; 27 (Suppl. 1): 207-9.
48. Ryle AP, Sanger F, Smith LF, Kitai R. The dissulphide bonds of insulin. Biochem J. 1955; 60: 541-56.
49. Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Science. 1967; 157: 697-700.
50. Rubenstein AH, Clark JL, Melani F, Steiner DF. Secretion of proinsulin, C-peptide by pancreatic cells and its circulation in blood. Nature. 1969; 224: 697-9.
51. Little RR, Rohlfing CL, Tennill AL, Madsen RW, Polonsky KS, Myers GL, et al. Standardization of C-peptide measurements. Clin Chem. 2008; 54: 1023-6.
52. Madsbad S, Sauerbrey N, Moller-Jensen B, Krarup T, Kuhl C. Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type I (insulin-dependent) diabetic patients. Acta Med Scand. 1987; 222: 71-4. (Pubitemid 17128913)
53. Ronnemaa T. Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients. Scand J Clin Lab Invest. 1986; 46: 345-9.
54. Menchini M, Meschi F, Lambiase R, Puzzovio M, Del Guercio MJ, Chiumello G. C-peptide response to arginine stimulation in diabetic children. J Pediatr. 1980; 96: 362-6.
55. Scheen AJ, Castillo MJ, Lefebvre PJ. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab. 1996; 22: 397-406.
56. Sjoberg S, Gunnarsson R, Ostman J. Residual C-peptide production in type I diabetes mellitus: a comparison of different methods of assessment and influence on glucose control. Acta Med Scand. 1983; 214: 231-7. (Pubitemid 14230862)
57. Heinze E, Beischer W, Keller L, Winkler G, Teller WM, Pfeiffer EF. C-peptide secretion during the remission phase of juvenile diabetes. Diabetes. 1978; 27: 670-6.
58. Hother-Nielsen O, Faber O, Sorensen NS, Beck-Nielsen H. Classification of newly diagnosed diabetic patients as insulin requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care. 1988; 11: 531-7.
59. Berger B, Stenstrom G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest. 2000; 60: 687-3.
60. Zangeneh F, Arora PS, Dyck PJ, Bekris L, Lernmark A, Achenbach SJ, et al. Effects of duration of type 2 diabetes mellitus on insulin secretion. Endocr Pract. 2006; 12: 388-93.
61. Niskanen L, Karjalainen J, Siitonen O, Uusitupa M. Metabolic evolution of type 2 diabetes: a 10-year follow-up from the time of diagnosis. J Intern Med. 1994; 236: 263-70. (Pubitemid 24283063)
62. Brandenburg D. History and diagnostic significance of C-Peptide. Exp Diabetes Res. 2008; 2008: 576862.
63. Balasubramanyam A, Garza G, Rodriguez L, Hampe CS, Gaur L, Lernmark A, et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care. 2006; 29: 2575-9.
64. Maldonado M, Hampe CS, Gaur L, D'Amico S, Iyer D, Hammerle LP, et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and ß-cell functional classification: prospective analysis and clinical outcomes. J Clin Endocrinol Metab. 2003; 88: 5090-8.
65. Mauvais-Jarvis F, Sobngwi E, Porcher R, Riveline JP, Kevorkian JP, Vaisse C, et al. Ketosis-prone type 2 diabetes inpatients of sub-Saharan African origin: clinical pathophysiology and natural history of β-cell dysfunction and insulin resistance. Diabetes. 2004; 53: 645-53.
66. Umpierrez GE, Woo W, Hagopian WA, Isaacs SD, Palmer JP, Gaur LK, et al. Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. Diabetes Care. 1999; 22: 1517-23.